Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ:CVKD
Total Valuation
Cadrenal Therapeutics, Inc. has a market cap or net worth of $10.83M. The enterprise value is $6.82M.
Market Cap$10.83M
Enterprise Value$6.82M
Share Statistics
Cadrenal Therapeutics, Inc. has 2,506,817 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,506,817
Owned by Insiders16.94%
Owned by Institutions1.08%
Financial Efficiency
Cadrenal Therapeutics, Inc.’s return on equity (ROE) is -4.83 and return on invested capital (ROIC) is -491.51%.
Return on Equity (ROE)-4.83
Return on Assets (ROA)-3.06
Return on Invested Capital (ROIC)-491.51%
Return on Capital Employed (ROCE)-4.92
Revenue Per Employee0.00
Profits Per Employee-3.31M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cadrenal Therapeutics, Inc. is ―. Cadrenal Therapeutics, Inc.’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio4.94
Price to Fair Value4.94
Price to FCF-1.07
Price to Operating Cash Flow-0.68
PEG Ratio0.04
Income Statement
In the last 12 months, Cadrenal Therapeutics, Inc. had revenue of 0.00 and earned -13.24M in profits. Earnings per share was -6.64.
Revenue0.00
Gross Profit0.00
Operating Income-13.46M
Pretax Income-13.24M
Net Income-13.24M
EBITDA-13.46M
Earnings Per Share (EPS)-6.64
Cash Flow
In the last 12 months, operating cash flow was -12.60M and capital expenditures -8.36K, giving a free cash flow of -12.61M billion.
Operating Cash Flow-12.60M
Free Cash Flow-12.61M
Free Cash Flow per Share-5.03
Dividends & Yields
Cadrenal Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.14
52-Week Price Change-71.20%
50-Day Moving Average6.60
200-Day Moving Average10.20
Relative Strength Index (RSI)30.27
Average Volume (3m)57.36K
Important Dates
Cadrenal Therapeutics, Inc. upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Cadrenal Therapeutics, Inc. as a current ratio of 2.72, with Debt / Equity ratio of 0.00%
Current Ratio2.72
Quick Ratio2.72
Debt to Market Cap0.00
Net Debt to EBITDA0.30
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cadrenal Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cadrenal Therapeutics, Inc. EV to EBITDA ratio is -0.71, with an EV/FCF ratio of -0.75.
EV to Sales0.00
EV to EBITDA-0.71
EV to Free Cash Flow-0.75
EV to Operating Cash Flow-0.75
Balance Sheet
Cadrenal Therapeutics, Inc. has $4.01M in cash and marketable securities with $0.00 in debt, giving a net cash position of $4.01M billion.
Cash & Marketable Securities$4.01M
Total Debt$0.00
Net Cash$4.01M
Net Cash Per Share$1.60
Tangible Book Value Per Share$1.37
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cadrenal Therapeutics, Inc. is $29.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$29.00
Price Target Upside571.30% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast-9.80%